Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long term. Here you will gain full access to all profitable insight available from our team of analysts. Learn more about Zacks Equity Research.
Outside the U.S., Acorda has partnered with Biogen Idec under very favorable terms. Fampridine-SR has blockbuster potential worldwide in our view. Plus, the company is extremely well-capitalized with over $290 million in cash, and management has commercial experience with current approved product Zanaflex.
These are among the best fundamentals in all of biotech. We reiterate our Outperform rating on the stock.
Bear of the Day Canon, Inc. (CAJ) - We believe the sharp appreciation of the yen is eroding Canon's (CAJ) revenue and profits. The company expects to improve profitability through product launches and cost-cutting efforts, and Canon has maintained its revenue and earnings forecast even though the third quarter was below expectations.
We expect revenue in 2009 to be hurt by weak consumer spending and the poor global economy, and believe the company will struggle to meet expectations in fiscal 2010. We maintain our estimates for the full year 2009. 2011 estimates have been added.
We also maintain our Underperform recommendation on CAJ shares, but increased our six-month target price to $30.00.
Analyst Interviews Alternative Energy With Zacks Equity Research Earlier this year, quite a few alternative energy companies were in the trough. These companies have recovered from their lows.
Zacks Industry Rank Analysis Out-of-Step Industries By Dirk Van Dijk Some of the most interesting investments are companies moving in different directions from their much larger sector.
View All Company Reports
Performance information for other Zacks’ portfolios and strategies is available at: http://www.zacks.com/performance
Copyright ©2009 ZACKS Investment Research, Inc ("ZACKS"). All Rights Reserved. The information, data, analyses and opinions contained herein (1) includes confidential and proprietary information licensed from ZACKS, (2) may not be copied or redistributed, for any purpose, (3) does not constitute investment advice offered by ZACKS, (4) are provided solely for informational purposes, and (5) are not warranted or represented to be correct, complete, accurate or timely. ZACKS shall not be responsible for investment decisions, damages or other losses resulting from, or related to, use of this information, data, analyses or opinions. Past performance is no guarantee of future performance. Investments in equities and other instruments are not guaranteed by any bank, are not insured by FDIC or any other agency, and involve investment risks, including possible loss of the principal involved.
One or more investment advisory accounts for which Zacks Investment Management acts as an investment advisor may own or have sold short securities and/or hold long and/or short positions in options reviewed in this publication, prior to the publication of such positions. Officers, directors and/or employees of Zacks Investment Management may own or have sold short securities and/or hold long and/or short positions in options reviewed in this publication.
Zacks Elite contains opinions, and none of the information contained therein constitutes a recommendation by Zacks Investment Research that any particular security, portfolio of securities, transaction, or investment strategy is suitable for any specific person. You further understand that the Zacks Elite will not advise you personally concerning the nature, potential, value or suitability of any particular security, portfolio of securities, transaction, investment strategy or other matter. None of the information contained in the Zacks Elite may be deemed to be investment advice as such information is impersonal and not tailored to the investment needs of any specific person. PLEASE DO NOT EMAIL Zacks Elite, Zacks Investment Research, or a Zacks Elite Representative for PERSONALIZED INVESTMENT ADVICE, WHICH THEY CANNOT PROVIDE.
